Kymera Therapeutics, Inc.
KYMR
$43.87
$2.054.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 44.71M | 58.89M | 47.07M | 87.56M | 88.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.71M | 58.89M | 47.07M | 87.56M | 88.55M |
| Cost of Revenue | 290.87M | 271.68M | 240.25M | 221.40M | 209.11M |
| Gross Profit | -246.16M | -212.80M | -193.18M | -133.84M | -120.56M |
| SG&A Expenses | 65.70M | 65.43M | 63.53M | 61.43M | 60.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 356.57M | 337.12M | 303.78M | 282.83M | 269.20M |
| Operating Income | -311.86M | -278.23M | -256.71M | -195.27M | -180.65M |
| Income Before Tax | -275.43M | -240.88M | -223.86M | -167.47M | -157.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -275.43 | -240.88 | -223.86 | -167.47 | -157.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -275.43M | -240.88M | -223.86M | -167.47M | -157.85M |
| EBIT | -311.86M | -278.23M | -256.71M | -195.27M | -180.65M |
| EBITDA | -305.86M | -272.47M | -251.54M | -190.16M | -176.64M |
| EPS Basic | -3.48 | -3.10 | -2.97 | -2.33 | -2.41 |
| Normalized Basic EPS | -2.17 | -1.94 | -1.81 | -1.41 | -1.46 |
| EPS Diluted | -3.48 | -3.10 | -2.97 | -2.33 | -2.41 |
| Normalized Diluted EPS | -2.17 | -1.94 | -1.81 | -1.41 | -1.46 |
| Average Basic Shares Outstanding | 316.71M | 309.32M | 299.94M | 278.48M | 260.77M |
| Average Diluted Shares Outstanding | 316.71M | 309.32M | 299.94M | 278.48M | 260.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |